ZA99723B - Recombinant proteins derived from HGF and MSP. - Google Patents

Recombinant proteins derived from HGF and MSP.

Info

Publication number: ZA99723B
Authority: ZA; South Africa
Prior art keywords: recombinant proteins; msp; hgf; proteins derived; deriving
Prior art date: 1998-01-30

Application number

ZA9900723A

Other languages

English (en)

Inventor

Enzo Medico

Paolo Michieli

Chlara Collesi

Gianfranco Caselli

Paolo Comoglio

Original Assignee

Dompe Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-30

Filing date

1999-01-29

Publication date

1999-07-29

1999-01-29 Application filed by Dompe Spa filed Critical Dompe Spa

1999-07-29 Publication of ZA99723B publication Critical patent/ZA99723B/xx

Links

102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 3
239000002246 antineoplastic agent Substances 0.000 abstract 2
230000006907 apoptotic process Effects 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
229940044683 chemotherapy drug Drugs 0.000 abstract 1
229940127089 cytotoxic agent Drugs 0.000 abstract 1
230000034994 death Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
238000011275 oncology therapy Methods 0.000 abstract 1
230000006798 recombination Effects 0.000 abstract 1
238000005215 recombination Methods 0.000 abstract 1
231100000331 toxic Toxicity 0.000 abstract 1
230000002588 toxic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ZA9900723A 1998-01-30 1999-01-29 Recombinant proteins derived from HGF and MSP. ZA99723B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT98MI000179A ITMI980179A1 (it)	1998-01-30	1998-01-30	Proteine ricombinanti derivate da hgf e msp

Publications (1)

Publication Number	Publication Date
ZA99723B true ZA99723B (en)	1999-07-29

Family

ID=11378771

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9900723A ZA99723B (en)	1998-01-30	1999-01-29	Recombinant proteins derived from HGF and MSP.

Country Status (14)

Country	Link
US (1)	US6551991B1 (de)
EP (1)	EP1049778B1 (de)
JP (1)	JP4478329B2 (de)
AT (1)	ATE335080T1 (de)
AU (1)	AU740490B2 (de)
CA (1)	CA2319211C (de)
DE (1)	DE69932592T2 (de)
ES (1)	ES2270581T3 (de)
HU (1)	HU226717B1 (de)
IL (2)	IL137564A0 (de)
IT (1)	ITMI980179A1 (de)
NZ (1)	NZ506005A (de)
WO (1)	WO1999038967A2 (de)
ZA (1)	ZA99723B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040138120A1 (en) *	2002-10-07	2004-07-15	Genentech, Inc.	Hepatocyte growth factor variants
EP1642586A4 (de) *	2003-06-06	2009-06-17	Kringle Pharma Inc	Zellhaltige zubereitungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5350836A (en) *	1989-10-12	1994-09-27	Ohio University	Growth hormone antagonists
ATE222603T1 (de) *	1992-05-18	2002-09-15	Genentech Inc	Hepatozytwachstumfaktor variante
WO1993023550A2 (en) *	1992-05-18	1993-11-25	Genentech, Inc.	Activation of oligomerizing receptors by using fused receptor ligands
CA2144081C (en)	1992-09-16	2004-11-30	Filip Roos	Protection against liver damage by hgf

1998
- 1998-01-30 IT IT98MI000179A patent/ITMI980179A1/it unknown
1999
- 1999-01-27 AT AT99903681T patent/ATE335080T1/de not_active IP Right Cessation
- 1999-01-27 US US09/600,991 patent/US6551991B1/en not_active Expired - Fee Related
- 1999-01-27 HU HU0104598A patent/HU226717B1/hu not_active IP Right Cessation
- 1999-01-27 AU AU24245/99A patent/AU740490B2/en not_active Ceased
- 1999-01-27 ES ES99903681T patent/ES2270581T3/es not_active Expired - Lifetime
- 1999-01-27 DE DE69932592T patent/DE69932592T2/de not_active Expired - Lifetime
- 1999-01-27 CA CA2319211A patent/CA2319211C/en not_active Expired - Fee Related
- 1999-01-27 NZ NZ506005A patent/NZ506005A/xx unknown
- 1999-01-27 EP EP99903681A patent/EP1049778B1/de not_active Expired - Lifetime
- 1999-01-27 IL IL13756499A patent/IL137564A0/xx active IP Right Grant
- 1999-01-27 JP JP2000529427A patent/JP4478329B2/ja not_active Expired - Lifetime
- 1999-01-27 WO PCT/EP1999/000478 patent/WO1999038967A2/en not_active Ceased
- 1999-01-29 ZA ZA9900723A patent/ZA99723B/xx unknown
2000
- 2000-07-27 IL IL137564A patent/IL137564A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1049778B1 (de)	2006-08-02
HUP0104598A1 (hu)	2002-03-28
IL137564A0 (en)	2001-07-24
JP2002501745A (ja)	2002-01-22
CA2319211C (en)	2010-10-26
ATE335080T1 (de)	2006-08-15
CA2319211A1 (en)	1999-08-05
US6551991B1 (en)	2003-04-22
WO1999038967A2 (en)	1999-08-05
DE69932592T2 (de)	2007-08-09
HU226717B1 (en)	2009-07-28
WO1999038967A3 (en)	1999-09-16
AU740490B2 (en)	2001-11-08
AU2424599A (en)	1999-08-16
ES2270581T3 (es)	2007-04-01
HUP0104598A3 (en)	2003-09-29
EP1049778A2 (de)	2000-11-08
NZ506005A (en)	2003-06-30
IL137564A (en)	2007-06-17
ITMI980179A1 (it)	1999-07-30
DE69932592D1 (de)	2006-09-14
JP4478329B2 (ja)	2010-06-09

Similar Documents

Publication	Publication Date	Title
BR0009670A (pt)	2002-01-15	Métodos de induzir morte de células de câncer e regressão de tumor
ATE63748T1 (de)	1991-06-15	Enzymwiderstandsfaehige immunomodulatorische peptide.
FI972086A7 (fi)	1997-05-15	Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset
BR9407956A (pt)	1996-11-26	Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
ATE242633T1 (de)	2003-06-15	Dialkylfumarate zur behandlung von autoimmunerkrankungen
IL197686A0 (en)	2011-07-31	Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
BR0007527A (pt)	2001-12-04	Fenilfenantridinas com atividade inibitória depde-iv
DE69533551D1 (de)	2004-10-28	Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
GB9415167D0 (en)	1994-09-14	Improvements relating to cancer therapy
GR3026602T3 (en)	1998-07-31	Morphogen-induced liver regeneration.
MX9800945A (es)	1998-04-30	Uso de griseofulvina para inhibir el crecimiento de canceres.
CA2234263A1 (fr)	1998-02-05	Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ATE433461T1 (de)	2009-06-15	Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ZA981609B (en)	1998-12-08	Method of treating a tumor
EP0214017A3 (en)	1989-07-26	Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
BR0009170A (pt)	2002-04-30	ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
DE69725882D1 (de)	2003-12-04	Adenovirus e4 proteine für induktion von zelltod
DE69533873D1 (de)	2005-01-27	Krebstherapie mit lymphotoxin
IL137564A0 (en)	2001-07-24	Recombinant proteins derived from hgf and msp
DE69815840D1 (de)	2003-07-31	Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
ATE232398T1 (de)	2003-02-15	Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
DE69814691D1 (de)	2003-06-18	Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
ATE78164T1 (de)	1992-08-15	Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
TR200000728T2 (tr)	2000-09-21	Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
GB9704046D0 (en)	1997-04-16	Arrestable therapeutic